Evidence map›Paper›PMID 41615627›Full record

ReviewApplied health economics and health policy2026

Indirect Effects in Health Economic Models of Vaccines: Should We Include Them, and How Do We Model Them?

Rachel J Oidtman, Min Huang, Walter A Orenstein, Matthew S Kelly, Zinan Yi, Elamin Elbasha, Michael Drummond

Abstract readReview
In one paragraph

Review in Applied health economics and health policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rachel J OidtmanMerck & Co., Inc., Rahway, NJ, USA. rachel.oidtman@merck.com.
Min HuangMerck & Co., Inc., Rahway, NJ, USA.
Walter A OrensteinSchool of Medicine, Emory University, Atlanta, GA, USA.
Matthew S KellyDivision of Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zinan YiMerck & Co., Inc., Rahway, NJ, USA.
Elamin ElbashaMerck & Co., Inc., Rahway, NJ, USA.
Michael DrummondCentre for Health Economics, University of York, Heslington, York, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indirect effects refer to the population-level effects of vaccination on vaccinated and unvaccinated individuals, including herd protection, serotype replacement, and age shifts, which can substantially impact the real-world effectiveness of vaccination programs. Despite their importance, most economic evaluations omit indirect effects, likely owing to the complexity of underlying mechanisms, data limitations, and difficulties in disentangling confounding factors. Static models and dynamic transmission models (DTMs) are two common approaches for incorporating indirect effects in economic evaluations. Static models rely on simplified assumptions and readily available data but often overlook the temporal and population-level dynamics of disease transmission. In contrast, DTMs account for complex factors (e.g., population mixing, serotype competition, and long-term epidemiological changes) but require more complex model structure and extensive data. In this article, we illustrate the applications, strengths, and limitations of these two modeling approaches through case studies. We demonstrate how choices of model structure and assumptions, data sources, and parameter estimation methodologies can influence projected epidemiological and economic outcomes, sometimes leading to divergent conclusions. While international guidelines increasingly recognize the importance of including indirect effects in economic evaluations, limited methodological guidance from National Immunization Technical Advisory Groups (NITAGs) and health technology assessment (HTA) bodies continues to hinder consistent implementation. This paper advocates for a collaborative effort among stakeholders to generate high-quality surveillance data and establish guidelines for methodological considerations to model indirect effects. Such efforts will improve the accuracy of epidemiological and economic assessments of vaccination programs and strengthen evidence-based decision-making in public health.

Indexed as

Immunization ProgramsModels, EconomicVaccinationVaccinesCost-Benefit AnalysisHumansVaccines

Identifiers

PMID41615627
PMCPMC13260020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.